Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2022-04-18 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of research data related to Bucillamine in COVID-19. It discusses scientific study results and ongoing clinical trials but does not contain financial statements, regulatory filings, or detailed financial data. It is an announcement of research findings rather than a formal financial or regulatory report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal filing type. The document is a general corporate announcement about research publication and clinical trial status, which fits best under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other categories.
2022-04-18 English
News release - English.pdf
Regulatory Filings
2022-04-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on the progress of a Phase 3 clinical trial for a drug related to COVID-19 treatment. It discusses expected regulatory submissions and trial enrollment timelines but does not contain any financial data, earnings information, or detailed financial reports. It is not an annual or interim report, nor is it a regulatory filing of financial nature. The content is focused on clinical trial progress and regulatory updates, typical of a general corporate announcement or regulatory update. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2022-03-02 English
Interim MD&A - English.pdf
Regulatory Filings
2022-03-02 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-03-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.